Surgical Outcomes of Adrenocortical Carcinoma; 20 Years of Experience in a Single Institution

김민지; Eun Jeong Ban; Soo Jung Jung; 손해영; 이초록; 강상욱; 정종주; 남기현; 정웅윤; 박정수

추천

검색

자료유형: 학술저널

저자정보: 김민지 Eun Jeong Ban Soo Jung Jung 손해영 이초록 강상욱 정종주 남기현 정웅윤 박정수

저널정보: 대한갑상선-내분비외과학회 The Journal of Endocrine Surgery The Journal of Endocrine Surgery 제14권 제4호

발행연도: 2014.1

수록면: 219 - 227 (9page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Adrenocortical carcinoma (ACC) is a rare malignant tumor. Early detection is difficult and prognosis is poor. We report on 20 years of ACC surgical experience at our institution. Methods: This study included 32 ACC patients who underwent surgical resection at the Department of Surgery of the Yonsei University Health System in South Korea between January 1990 and February 2012. We reviewed these 32 patients and retrospectively analyzed long-term clinical outcomes and prognosis after radical surgery for ACC. Results: The median age of the 32 patients at diagnosis was 42.25 years (range 3∼81 years). There were 16 (50%) female and 16 (50%) male patients. Mean tumor size was 12.36 cm (range 1.8∼20 cm). Twenty-five patients (78.12%) had nonfunctioning tumors while the other seven patients (21.87%) had functioning tumors. Seventeen patients (53.12%) were classified as stage II, two (6.25%) as stage III, and 13 (40.62%) as stage IV. Fourteen patients underwent radical surgical resection, while 14 patients received adjuvant chemotherapy, two received adjuvant radiotherapy, and two received adjuvant chemoradiation. Four patients were lost to follow-up. Among the remaining 28 patients, 15 patients survived. The 5- and 10-year overall survival was 60.6% and 37.8%, respectively (median survival=85±24.3 months). Seventeen patients (53%) experienced disease recurrence. Five- and 10-year recurrence-free survival was 41.5% and 29.7%, respectively (median survival=18±5.5 months). Conclusion: Early stage at diagnosis and surgical resection were the most important prognostic factors associated with prolonged survival. The role of additional therapy remains controversial and new agents should continually be evaluated for efficacy.

#Adrenocortical carcinoma #Surgical resection #Survival

참고문헌 (25)

참고문헌 신청

Allolio B / 2004 / Management of adrenocortical carcinoma / Clin Endocrinol 60 : 273 ~ 287

Aubert S / 2005 / Weiss system: a still in-use diagnostic tool for the assessment of adrenocortical malignancy / Ann Pathol 25 : 545 ~ 554

Barzon L / 1997 / Adrenocortical carcinoma: experience in 45 patients / Oncology 54 : 490 ~ 496

Baudin E / 2001 / Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma / Cancer 92 : 13

Edge SB / 2010 / AJCC Cancer Staging Manual / Springer : 516 ~ 517